Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

LAMA add‐on vs long‐acting beta2‐agonists (LABA) add‐on

Serious adverse events 22 weeks · adults with asthma not well controlled on ICS

Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting… 2015 · Cochrane Headline outcomes only
OR 0.84 [0.41, 1.73]
4 studies · 2012 participants
Low